The transition period from the hospital to the outpatient setting is a critical phase when managing heart failure. A well-structured transition is paramount and helps to ensure a tight follow-up schedule for the heart failure patient, thereby improving treatment outcomes. This article aims to provide guidance for the first three follow-up visits after hospital discharge, with a focus on monitoring heart failure patients and up-titrating their medication in primary care.
Introduction
Heart failure (HF) is a serious chronic condition associated with periodic exacerbations leading to frequent hospitalisation [1] . Indeed, it is the leading cause of hospitalisation in patients over 65 years of age [1] [2] [3] . HF patients are discharged from the hospital in a vulnerable phase characterised by high mortality and morbidity. In a Swiss trial, approximately 20% of HF patients were readmitted to the hospital within the first 30 days of discharge [4] . Similarly, data gathered from two other studies conducted in Switzerland showed that at 3 months mortality was 18% and the rate of rehospitalisation was 26% [3, 5] .
Several strategies have been developed to reduce mortality and morbidity during the vulnerable post-discharge period, including coordinated discharge planning and the development of a well-structured follow-up treatment plan [1] . This seems to be an area where cardiology could learn a lot from oncology with its predefined treatment schedules aiming to best balance treatment efficacy and tolerability. An integrative and collaborative patient care approach following hospital discharge has been shown to reduce the mortality risk by approximately 50% (from 15.5% to 7.2%) [6] . In particular, prescheduled follow-up visits, adherence to therapy and up-titration of HF medication are important aspects of reducing the mortality risk during the transition phase after hospital discharge [1] . Consequently, according to European Society of Cardiology (ESC) Guidelines, patients with chronic HF should be followed up in a multidisciplinary environment (evidence level IA) in which general practitioners (GPs) and cardiologists play a key role [1, 7, 8] .
The aim of this consensus paper is to set clear treatment targets for the first three follow-up visits, and to provide GPs and cardiologists with recommendations for an optimal patient follow-up during the transition phase after discharge of HF patients hospitalised for acute decompensation in Switzerland. We address the aspect of feasibility, highlighting current hurdles for implementation, and also concepts on how to overcome them. In particular, these recommendations also provide guidance on the optimal monitoring of HF patients when up-titrating HF medication, which may be challenging owing to its tolerability, concomitant comorbidities and polypharmacy. The recommendations for monitoring apply universally to all HF patients, whereas the recommendations for up-titration of disease-modifying drugs are specific for HF with reduced ejection fraction (HFrEF)
The benefit of a well-structured transition phase
There is a growing body of evidence suggesting that HF patients are particularly vulnerable to disruptions in care during the transition phase [7, 9, 10] . For example, it has been shown that readmission rates can be reduced if the first outpatient follow-up visit is scheduled prior to hospital discharge [1] . In line with this study, the 2016 ESC guidelines for acute and chronic HF propose a care plan ensuring a well-structured transition phase to improve treatment outcomes [1] .
The criteria for a well-structured transition phase are detailed in figure 1 . The discharge letter ideally provides information on the clinical course including body weight, blood pressure, potassium and renal function prior to discharge, the therapy initiated in hospital and -importantly -recommendations on the follow-up schedule and uptitration strategy [1, 11] . The HF diary developed by the Schweizerische Herzstiftung should be given to the patient at discharge or at the latest at the first outpatient visit, as it contributes to a well-structured transition from hospital to primary care [12] . In the HF patient's daily diary, "My heart diary", provided by the Swiss Heart Failure foundation, the patient can (or should) record body weight, blood pressure, heart rate, and other symptom-related observations [13] . It is suggested that patients bring their HF diary to each follow-up visit with their GP or cardiologist. Another cornerstone of the HF diary is a detailed medication plan. This plan should list the prescribed drugs, including their active substances and brand names, as well as provide instructions on how and when the drugs should be taken. The GP and the cardiologist should be notified whether the patient has been informed about the prognosis of the disease while still at hospital or if the patient has expressed wishes regarding life-prolonging measures and palliative care [14] . In the case of patients with severe HF, the patient, the cardiologist and the GP should be involved in the decision to transition to palliative care. However, it is challenging to select the time-point for this transition as symptoms and quality of life keep changing for HF patients. Thus, it is recommended to regularly assess the patients and analyse their palliative scores, which provide an objective assessment of the patient's condition [1] .
To ensure a timely follow-up schedule, a collaborative care network with HF specialists, cardiologists and GPs should be established. Consistently with the 2016 ESC guidelines on HF, the present author group recommends that the first follow-up visit take place within the first 7-10 days after hospital discharge [1] . Patients with severe HF, however, should see a GP or cardiologist within 1-3 days [15] [16] [17] . Recommendations for monitoring HF patients beyond the first follow-up visit are currently limited and depend on the individual patient's needs. This author group further suggests that the second visit take place 7-10 days after the first visit. The interval between follow-up visits can be increased for the third and later follow-up visits depending on the patient's clinical status. A referral to a cardiologist, on the other hand, is recommended every 3 months for patients with New York Heart Association (NYHA) stage III-IV HF [18, 19] .
Together these measures ensure a close collaboration between GPs and cardiologists, thus enabling HF patients to receive the right support and care after hospital discharge. Furthermore, these measures are a prerequisite for optimal follow-up and up-titration strategies and, therefore, contribute to reducing the risk of death or rehospitalisation [1] .
Feasibility
Several hurdles for implementation exist. First, most GPs/ cardiologists have busy schedules, making it challenging to add on additional patients at rather short notice. Second, GPs/cardiologists may not have all relevant medical infor- [1] , Yancy 2013/2017 [47, 48] and the Canadian Cardiovascular Society 2017 [30] .
mation of the recent hospitalisation available early on after discharge owing to delays in the finalisation of the discharge letter or lack of details in the discharge letter (e.g., missing details on body weight, blood pressure, potassium and renal function). Third, some patients may not have a GP/cardiologist at the time of hospitalisation. Fourth, frailty may limit the ability of the patient to visit the office of the GP/cardiologist.
For successful implementation of the transition programme, each of these hurdles must be addressed and ultimately overcome. To improve practical feasibility, the implementation of cardiology and/or HF networks that share patient information and use common electronic health records, joint online booking systems for GP/cardiology slots (similar to those used extensively to book hotel rooms worldwide), such as docbox, nurse-coordinated HF management programmes [20, 21] , and tele-monitoring programmes, such as the Swiss Care4Cardio, will all have important roles [22, 23] .
General assessments during follow-up visits
Recommended assessments to be performed during the first three follow-up visits with the GP or the cardiologist are summarised in table 1 [1] . These include the evaluation of risk factors that increase the risk of rehospitalisation due to HF. Monitoring of physical symptoms (rales, oedema, body weight changes), laboratory parameters (B-type natriuretic peptide [BNP] or N-terminal pro b-type natriuretic peptide [NT-pro-BNP], electrolytes, haemoglobin, renal function), and drug-related adverse events (hypotension, hyperkalaemia, worsening renal function) are likewise of particular relevance [1, 26] .
Patient education
The follow-up visits should also be used to educate the HF patients on the importance of self-monitoring body weight and other signs /symptoms of deterioration. Besides the "heart failure diary", patients may use apps, such "life with heart failure" or the "electronic heart failure diary", for self-monitoring [27] . This authors group considers patient education and empowerment an import pillar of HF management. In addition, patients need to learn how to react to imminent decompensation (calling their GP, self-adjusting the diuretic dose).
Medication management after hospital discharge
The importance of up-titration after hospital discharge Treatment of HF with angiotensin converting-enzyme inhibitors (ACEIs), or angiotensin II receptor blockers (ARBs) if the ACEI is not tolerated, angiotensin receptorneprilysin inhibitor (ARNI), beta-blockers and mineralocorticoid receptor antagonists (MRAs) form the basis of the management of patients with HFrEF ( fig. 2 ). Adjustment and up-titration of these therapeutic agents are critical for successful HF management. Based on pivotal trials, the 2016 ESC guidelines on HF recommend tight followup and up-titration schedules until the highest tolerated dose is achieved [1] . However, only a minority of patients enrolled in the ESC Heart Failure Long-Term Registry received the target dose of an ACEI (29% of patients) or beta-blocker (18% of patients) despite their positive impact [28] . Conversely, a careful reduction of loop diuretics may be feasible in the majority of stable chronic HF patients without signs of volume overload [29] . Guidance on up-titrating heart failure medication Table 2 provides both GPs and cardiologists with a checklist for initiating and up-titrating HF medication. An overview is depicted in figure 1 . This up-titration strategy should be followed in all HFrEF patients as long as the therapy is tolerated. The up-titration strategy should be adjusted in the case of adverse events such as hypotension, hyperkalaemia or worsening renal function [1, 30] . Rec-ommendations for adjusting HF medication in HFrEF patients experiencing such adverse events are summarised in table 3.
Management of adverse events is part of the up-titration strategy. Patients with asymptomatic hypotension (systolic blood pressure [SBP] 90-100 mm Hg) usually do not require any changes to therapy [45] . In patients with symptomatic hypotension (characterised by dizziness, light-head- edness and confusion; SBP ≤90 mm Hg), however, treatment with nitrates, calcium-channel blockers and other vasodilators should be either stopped entirely or administered at reduced doses [45] .
The probability for symptomatic hypotension is increased in patients with volume and sodium depletion [31-33, 35-37, 44] . Therefore, a reduction of the diuretic dose should be considered in compensated patients not showing signs or symptoms of congestion [45] . If these measures do not improve the patient's clinical status, the dose of ACEi, ARB, ARNI or beta-blocker may be temporarily reduced in a step-by-step manner [38] [39] [40] [41] and the patient has to be reassessed within one week [45] . Renal insufficiency may also increase the risk of hypotension [32, 35] . Furthermore, postural hypotension in HF patients with autonomic dysfunction or stroke can limit the optimal dosing of HF medication [1] . In these patients, a reduction of the diuretic dose may reduce the severity of the interaction [1] . Treatment of other pharmacological conditions such as depression (tricyclic antidepressants) or prostatic obstruction (alpha-adrenoceptor blockers) may cause hypotensive interactions with HF medication [1] .
As hyperkalaemia may occur in HF patients, regular monitoring of serum potassium levels is necessary [1] . Particularly in dehydrated or septic patients, serum potassium, creatinine and urea levels should be closely followed [45] . Additional risk factors for hyperkalaemia include age, renal failure and diabetes mellitus [43] . If serum potassium levels increase to ≥5.5 mmol/l, the doses of potassiumretaining agents and renin-angiotensin-aldosterone system (RAAS) inhibitors should be halved and levels rechecked after few days. Short term cessation is required if potassium rises to >6.0 mmol [1] . However, RAAS inhibitors should be reintroduced as soon as possible with continued close monitoring of potassium levels [1] .
Furthermore, worsening renal function or chronic kidney disease (CKD) are also commonly seen among HF patients [1] . Both CKD and HF share many risk factors, including diabetes, hypertension and hyperlipidaemia [1] . Heart failure patients are more vulnerable to acute renal failure following a destabilising event, such as a dehydrating illness, over-diuresis or the addition of nephrotoxic medication (e.g., antibiotics such as trimethoprim or gentamicin, or non-steroidal anti-inflammatory drugs, which are even contraindicated in HFrEF) [1] . Worsening renal function is common during initiation and up-titration of RAAS inhibitors [1] . Usually, the reduction in renal function is minor and should not lead to treatment discontinuation [1] . However, patients showing a substantial increase in serum creatinine levels (50% above baseline, 266 μmol/l / 3 mg/ dl or estimated glomerular filtration rate <25 ml/min/1.73 m 2 ) should be evaluated thoroughly and assessed for possible renal artery stenosis, excessive hyper-or hypovolaemia and concomitant medication [1] .
Limitations
Many recommendations provided in this review are supported by the latest European Society of Cardiology and American Heart Association / American College of Cardiology guidelines for the management of patients with HF (see also fig. 1 ). However, as we tried to provide as concrete and specific suggestions as possible to facilitate im- [1, 44] .
Adverse event ACEI/ARB/ARNI BB MRA Diuretic
Worsening signs or symptoms (increasing dyspnoea, fatigue, oedema, weight gain)
In patients with signs of increasing congestion, the diuretic dose should be increased.
In the event of severe deterioration, the BB dose should be reduced to 50%.
In the case of marked fatigue, the BB dose should be reduced to 50% and it should be taken in the night. The patient should be reassessed within 1-2 weeks. In the case of renal dysfunction, concomitant medication should be evaluated and a temporary dose reduction or withdrawal of ARNI is recommended [44] . ARNI therapy is contra-indicated in patients with eGFR <10ml/min/1.73m [1, 44] .
Asymptomatic hypotension
No change in therapy required. [44] . If the increase in potassium levels persists above ≥5.5 mmol/l, the ACEI (or ARB) dose should be reduced to half and blood chemistry re-checked within 1-2 weeks. ACEI (or ARB) therapy should be stopped temporarily if potassium levels rise to >6.0 mmol/l. In the event of hyperkalaemia, concomitant medication should be evaluated and a temporary dose reduction or withdrawal of ARNI is recommended [44] No change in therapy required. 
Conclusions
Managing HF successfully after hospital discharge requires a seamless interaction between the patient, the GP and the cardiologist [15] . In particular, the transition phase after hospital discharge is a critical and vulnerable phase in the management of HF [45] . Here, both GPs and cardiologists have an important role in monitoring and treating HF patients. In this article, we provide a summary of recommendations on how to up-titrate HF medication, which clinical and biomedical parameters to assess during the follow-up visits and how the patients can contribute to optimising their treatment outcomes. A well-structured transition phase is critical in HF management and the management of chronic diseases in general, especially considering that the proportion of patients with chronic diseases is continuously increasing [46] .
Clinical relevance
Heart failure is a serious chronic disease associated with frequent hospitalisation [1] [2] [3] [4] . The transition from hospital to primary care is a critical and vulnerable phase requiring close collaboration between patient, GP and cardiologist [1] . A cornerstone of follow-up care is the up-titration of HF medication. However, only a minority of HF patients achieve the target dose for ACEi and beta-blockers [28] . This article provides both GPs and cardiologists with suggested up-titration strategies and the optimal management of adverse events in an attempt to further improve HF management in Switzerland.
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